iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
iBio to announce 3rd target in Astral Bio Collaboration
Conference call Tuesday, June 24 at 8:30 a.m. ET
SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibody medicines—targeted, longer-lasting, and potentially better tolerated therapies with more sustainable efficacy. Dr. Brenner will present a strategic overview of the obesity strategy, including details on their long acting Myostatin, IBIO-600, new preclinical data on Activin E and, more safe and effective treatment options.The webcast of the live call may be accessed on the Investors section of the iBio website at ir.ibioinc.com/news-events/ir-calendar. A replay of the webcast will be available on the iBio website for approximately 60 days following the presentation.To join the live call, participants need to access this link for dial-in numbers and a unique participation code.
About iBio, Inc.
iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Any statements contained in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include statements regarding pioneering the next generation of antibody medicines, which are potentially better tolerated therapies with more sustainable efficacy, and Activin E and amylin agonist, which are promising pathways for more safe and effective treatment options. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact: iBio, Inc. Investor Relations ir@ibioinc.com
Media Contacts: Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 or (646) 942-5604
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Skift
26 minutes ago
- Skift
Virgin Hotels Chicago Sold, Brooklyn's Hotel Indigo Sold
The DJIA rose 208 points on Friday, while the Nasdaq was up 50, the S&P 500 rose 25 points, and the 10-year treasury yield was down .02 to 4.39%. Lodging stocks were modestly higher. Virgin Hotels has sold its 250-room hotel in Chicago to a firm specializing in converting properties into timeshare investments. The hotel was sold for just under $77.4 million to an affiliate of Accelerated Assets, according to online property records. The sale comes at an apparent loss to Virgin Hotels and its development partner on the project, Lionstone Development. It's unclear what Accelerated Assets has planned for the Chicago hotel, but the firm's business model is to acquire, develop and finance properties where individuals buy into timeshare ownership stakes. JLL brokers represented the seller. For the second time in a month, Park Hotels & Resorts is putting a prominent Chicago property on the market for sale. Park
Yahoo
29 minutes ago
- Yahoo
Old Second Bancorp Inc (OSBC) Q2 2025 Earnings Call Highlights: Strong Net Income Amidst ...
Net Income: $21.8 million or $0.48 per diluted share. Return on Assets: 1.53%. Return on Average Tangible Common Equity: 15.29%. Tax Equivalent Efficiency Ratio: 54.54%. Tangible Equity Ratio: Increased by 49 basis points to 10.83% from last quarter. Common Equity Tier 1: 13.77%, up from 13.47% last quarter. Net Interest Margin: Decreased 3 basis points to 4.85% from last quarter. Total Cost of Deposits: 84 basis points for the second quarter. Loan-to-Deposit Ratio: 83.3% as of June 30. Total Loans Increase: $58.4 million from last quarter. Allowance for Credit Losses on Loans: Increased to $43 million or 1.08% of total loans. Noninterest Income: Wealth management fees increased by $324,000 or 11.7%; service charges on deposits increased by $280,000 or 11.2%. Noninterest Expense: $1.1 million less than the prior linked quarter. Average Deposits Increase: $51 million or 1.1% quarter-over-quarter. Share Repurchase: Approximately 327,000 shares repurchased in a privately negotiated transaction. Warning! GuruFocus has detected 5 Warning Sign with OSBC. Release Date: July 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Old Second Bancorp Inc (NASDAQ:OSBC) reported a strong net income of $21.8 million or $0.48 per diluted share for the second quarter. The company's return on average tangible common equity was 15.29%, indicating strong profitability. The tangible equity ratio increased by 49 basis points from the previous quarter, showing improved capital strength. Net interest income increased by $1.3 million or 2.1% compared to the prior quarter, reflecting strong margin performance. The acquisition of Evergreen Bank is expected to enhance profitability, with the bank performing ahead of initial expectations. Negative Points The second quarter earnings were impacted by a $531,000 MSR mark-to-market loss and an $810,000 charge in merger-related expenses. Net interest margin decreased by 3 basis points compared to the previous quarter. The loan-to-deposit ratio increased to 83.3%, indicating a higher reliance on deposits for loan funding. Noninterest expense increased by $5.5 million year-over-year, driven by higher salaries, employee benefits, and occupancy costs. The integration of Evergreen Bank is expected to result in a 'messy' next quarter with acquisition-related expenses. Q & A Highlights Q: What is the expected timing for the Evergreen Bank conversion, and what is the anticipated expense run rate? A: Bradley Adams, CFO and COO, stated that the conversion is expected to occur in the early to mid-fourth quarter. By the time they report the fourth quarter, the operating expenses should be closer to the final run rate, with the first quarter of the next year being relatively clean. Q: Can you provide more details about the owner-occupied CRE that was classified? A: James Eccher, CEO, explained that it stems from a large healthcare transaction in Oregon. They do not foresee a loss as they are in a strong collateral position with a 70% covered loan-to-value. The facility had restrictions from the state of Oregon, but these have been lifted, and cash flow is expected to improve. Q: How are commercial clients feeling about growth and loan closures given the current economic climate? A: James Eccher noted that commercial clients are handling tariff uncertainty well, though CapEx appetite has been muted. There is growth in leasing and commercial real estate, with a strong second-half pipeline expected, especially with the Evergreen Bank's powersports area. Q: What is the outlook for charge-offs, especially with the Evergreen acquisition? A: James Eccher mentioned that while powersports lending can have higher loss rates (1% to 1.5%), the portfolio's average coupon is around 9%, which balances the risk. Bradley Adams added that a 30 basis point charge-off rate going forward is reasonable. Q: How will the margin respond to a potential 25 basis point Fed rate cut? A: Bradley Adams expressed skepticism about a rate cut this year, noting that the margin is less sensitive to rate changes due to balance sheet movements. He estimated a 4 basis point impact per 25 basis point cut, but emphasized that internal adjustments are more influential. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
29 minutes ago
- Yahoo
Southern Missouri Bancorp Inc (SMBC) Q4 2025 Earnings Call Highlights: Strong Earnings Growth ...
Release Date: July 24, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Southern Missouri Bancorp Inc (NASDAQ:SMBC) reported a year-over-year earnings growth of 17%, with earnings per share increasing from $4.42 in fiscal '24 to $5.18 in fiscal '25. The company saw a tangible book value per share increase by 14% over the last 12 months, reaching $41.87. Net interest margin improved to 3.46% from 3.39% in the previous quarter, driven by loan yield expansion and lower funding costs. Gross loan balances increased by 7.6% annualized during the quarter, indicating strong loan growth. Southern Missouri Bancorp Inc (NASDAQ:SMBC) announced an 8.7% increase in quarterly dividends, bringing it to $0.25 per share, reflecting confidence in their financial position. Negative Points Credit quality has deteriorated somewhat, with non-performing loans increasing by $1.1 million compared to the last quarter. Provision for credit losses rose to $2.5 million, up from $932,000 in the previous quarter, indicating increased credit risk. The agricultural segment is facing challenges with rising input costs and lower commodity prices, impacting farmer profitability. There is an expectation of higher prepayment activity in the near term, which could slow net loan growth. The company experienced a $3.8 million charge-off related to a special purpose CRE loan, highlighting ongoing credit challenges. Q & A Highlights Warning! GuruFocus has detected 2 Warning Sign with SMBC. Q: Can you provide more details on the loan growth throughout the quarter and any expectations for prepayments in the near term? A: Our loan growth was steady over the entire quarter, with loans in the pipeline consistently added. Regarding prepayments, we have not seen them yet, but several larger credits have indicated plans to pay off soon, primarily in our non-owner occupied commercial real estate sector. Q: What are your expectations for the net interest margin, especially if there are Fed rate cuts? A: We are currently more neutral to rate movements due to higher levels of excess cash. As this cash is deployed through loan growth, we may become more liability sensitive. We expect natural expansion from loan origination activity and renewals repricing at higher rates than our current portfolio. Q: How is the competitive environment for deposits, and what are your strategies regarding CDs? A: The deposit competition has been more reasonable over the last 6 to 9 months, although there was a slight pickup in July. We don't expect growth to be as heavily weighted towards CDs this year, given our strong funding position. We aim to be less aggressive on the CD side, which might slow growth relative to non-maturity deposits. Q: Can you elaborate on the credit charge-offs and any potential future appraisals? A: We wrote down the balance on one loan after an appraisal came in lower than expected. This was due to a special purpose entity operating it with above-market lease rates. We might see additional charge-offs on other remaining buildings, and we have 42% of the balance in specific reserve. Q: Are you seeing an increase in M&A discussions, and how do you view stock buybacks in the current environment? A: There are more calls from investment bankers, but we haven't seen a significant increase in actionable items. Regarding stock buybacks, it depends on our trading relative to tangible book value. We believe a potential M&A transaction could have a shorter earn-back period than repurchasing shares. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
